Affiliation:
1. Department of Chemistry, Queen’s University, Kingston, Ontario, K7L 3N6, Canada.
Abstract
The ideal neuromuscular blocking agent (NMBA) is regarded as being a non-depolarizing equivalent of succinylcholine, having a rapid onset and short duration of action, with minimal side effects. In the absence of a single drug, the administration of an aminosteroid NMBA, such as rocuronium, followed by reversal using an acetylcholinesterase inhibitor, such as neostigmine, is commonly employed. A different and safer approach to rapidly reversing the action of the NMBA, by encapsulating it with a macrocyclic or acyclic host molecule, such as the cyclodextrin sugammadex or more recently, cucurbituril-type hosts such as cyclic cucurbit[7]uril and the acyclic glycoluril tetramer calabadion 1, is described.
Subject
Drug Discovery,Pharmacology,Molecular Medicine
Reference101 articles.
1. MirakhurRK. Neuromuscular Blocking and Reversal Agents. In:Pharmacology for Anaesthesiologists.Fee JPH, Bovill JG (Eds). Taylor & Francis, FL, USA,94–104 (2005).
2. NaguibM, Brull SJ. Pharmacology of Neuromuscular Blockers. In:Neuroscientific Foundations of Anesthesiology.Mashour GA, Lydic R (Eds). Oxford University Press, London, UK,211–230 (2011).
3. LienCA, Eikermann M. Neuromuscular Blockers and Reversal Drugs. In:Pharmacology and Physiology for Anesthesia.Hemmings HC, Egan TD (Eds). Saunders, MO, USA,325–348 (2013).
4. Molecular architecture of the neuromuscular junction
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献